Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Aids 2022 preview – Gilead shoots for an HIV cure
But progress – or lack thereof – with lenacapavir is a more immediate concern.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Asco 2022 – investors clutch at the Tigit straws
Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.
Asco 2022 – great expectations for Adicet, Arcellx and PMV
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
